Citadel Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-68,854
| Closed | -$1.24M | – | 11177 |
|
|
2020
Q2 | $1.24M | Sell |
68,854
-145,799
| -68% | -$2.03M | ﹤0.01% | 5429 |
|
|
2020
Q1 | $1.53M | Sell |
214,653
-296,238
| -58% | -$3.7M | ﹤0.01% | 4586 |
|
|
2019
Q4 | $12.2M | Buy |
510,891
+208,700
| +69% | +$5.76M | 0.01% | 1997 |
|
|
2019
Q3 | $8.11M | Sell |
302,191
-96,689
| -24% | -$2.71M | ﹤0.01% | 2470 |
|
|
2019
Q2 | $10.8M | Buy |
398,880
+357,300
| +859% | +$11.2M | 0.01% | 2085 |
|
|
2019
Q1 | $1.44M | Sell |
41,580
-29,201
| -41% | -$843K | ﹤0.01% | 4969 |
|
|
2018
Q4 | $1.38M | Sell |
70,781
-244,573
| -78% | -$5.03M | ﹤0.01% | 4770 |
|
|
2018
Q3 | $8.4M | Buy |
315,354
+161,580
| +105% | +$5.28M | ﹤0.01% | 2335 |
|
|
2018
Q2 | $5.81M | Buy |
153,774
+100,106
| +187% | +$3.83M | ﹤0.01% | 2566 |
|
|
2018
Q1 | $1.75M | Buy |
53,668
+27,418
| +104% | +$1.2M | ﹤0.01% | 3941 |
|
|
2017
Q4 | $1.28M | Sell |
26,250
-1,022,536
| -97% | -$51.7M | ﹤0.01% | 4295 |
|
|
2017
Q3 | $56.7M | Buy |
1,048,786
+560,144
| +115% | +$32.9M | 0.04% | 485 |
|
|
2017
Q2 | $27.4M | Buy |
488,642
+218,609
| +81% | +$8.76M | 0.02% | 807 |
|
|
2017
Q1 | $10.6M | Sell |
270,033
-62,764
| -19% | -$2M | 0.01% | 1393 |
|
|
2016
Q4 | $7.47M | Buy |
332,797
+222,321
| +201% | +$4.34M | 0.01% | 1613 |
|
|
2016
Q3 | $2.51M | Buy |
110,476
+78,171
| +242% | +$1.83M | ﹤0.01% | 2707 |
|
|
2016
Q2 | $762K | Sell |
32,305
-96,555
| -75% | -$2.38M | ﹤0.01% | 3921 |
|
|
2016
Q1 | $2.63M | Sell |
128,860
-1,015,870
| -89% | -$32.2M | ﹤0.01% | 2383 |
|
|
2015
Q4 | $58.9M | Sell |
1,144,730
-50,986
| -4% | -$2.47M | 0.06% | 331 |
|
|
2015
Q3 | $51M | Sell |
1,195,716
-74,472
| -6% | -$3.59M | 0.05% | 422 |
|
|
2015
Q2 | $57.9M | Buy |
1,270,188
+303,618
| +31% | +$12.2M | 0.05% | 436 |
|
|
2015
Q1 | $36.7M | Buy |
966,570
+290,598
| +43% | +$9.98M | 0.03% | 630 |
|
|
2014
Q4 | $19.1M | Buy |
675,972
+605,600
| +861% | +$16.8M | 0.02% | 975 |
|
|
2014
Q3 | $1.78M | Sell |
70,372
-114,635
| -62% | -$3.02M | ﹤0.01% | 2983 |
|
|
2014
Q2 | $5.4M | Buy |
185,007
+169,445
| +1,089% | +$4.1M | 0.01% | 1763 |
|
|
2014
Q1 | $403K | Buy |
+15,562
| New | +$415K | ﹤0.01% | 4656 |
|
Citadel Advisors's PTLA Position: Q3 2020 in Review
Citadel Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 68,854 shares — an estimated $1.24M sold.
Citadel Advisors first reported a position in PTLA in Q1 2014 and held it in 26 quarters. The position peaked at $58.9M in Q4 2015. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.
- Citadel Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Citadel Advisors sold 68,854 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $1.24M.
- Citadel Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 26 quarters.
- Citadel Advisors's Portola Pharmaceuticals, Inc. position peaked at $58.9M in Q4 2015.
- 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.
Based on Citadel Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.